These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1008 related items for PubMed ID: 19476428

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.
    Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM.
    Int J Infect Dis; 2010 Oct; 14(10):e868-75. PubMed ID: 20655261
    [Abstract] [Full Text] [Related]

  • 6. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.
    Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM.
    Vaccine; 2010 Jan 08; 28(3):657-63. PubMed ID: 19895922
    [Abstract] [Full Text] [Related]

  • 7. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R, Reisinger K, Block SL, Izu A, Odrljin T, Dull P.
    J Pediatr; 2014 Jun 08; 164(6):1409-15.e4. PubMed ID: 24657122
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J, Drazan D, Czajka H, Maguire J, Pregaldien JL, Seppa I, Maansson R, O'Neill R, Balmer P, Jodar L, Jansen KU, Anderson AS, Perez JL, Beeslaar J.
    Lancet Infect Dis; 2023 Dec 08; 23(12):1370-1382. PubMed ID: 37579773
    [Abstract] [Full Text] [Related]

  • 9. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants.
    Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P.
    Pediatr Infect Dis J; 2012 Jan 08; 31(1):64-71. PubMed ID: 22094635
    [Abstract] [Full Text] [Related]

  • 10. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL, Szenborn L, Daly W, Jackowska T, D'Agostino D, Han L, Dull PM, Smolenov I.
    Vaccine; 2015 May 15; 33(21):2500-10. PubMed ID: 25795256
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2-18 years in Taiwan: results of an open label study.
    Huang LM, Chiu NC, Yeh SJ, Bhusal C, Arora AK.
    Vaccine; 2014 Sep 08; 32(40):5177-84. PubMed ID: 25075804
    [Abstract] [Full Text] [Related]

  • 12. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
    Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM.
    Pediatr Infect Dis J; 2013 Apr 08; 32(4):e170-7. PubMed ID: 23114372
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C.
    Pediatr Infect Dis J; 2012 Jan 08; 31(1):e15-23. PubMed ID: 22094636
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years.
    Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D.
    Vaccine; 2009 Jan 01; 27(1):161-8. PubMed ID: 18834910
    [Abstract] [Full Text] [Related]

  • 17. Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age.
    Johnston W, Essink B, Kirstein J, Forleo-Neto E, Percell S, Han L, Keshavan P, Smolenov I.
    Pediatr Infect Dis J; 2016 Jan 01; 35(1):e19-27. PubMed ID: 26398741
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M.
    Vaccine; 2016 Oct 17; 34(44):5273-5278. PubMed ID: 27642132
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
    Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ.
    JAMA; 2008 Jan 09; 299(2):173-84. PubMed ID: 18182599
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.
    Pediatr Infect Dis J; 2015 Dec 09; 34(12):e298-307. PubMed ID: 26780033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.